

L11 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1


ACCESSION NUMBER: 2003:799397 CAPLUS

DOCUMENT NUMBER: 139:336696

TITLE: Treatment of chronic **graft-versus-host** disease with **anti-CD20** chimeric monoclonal antibody

AUTHOR(S): Ratanatharathorn, Voravit; Ayash, Lois; Reynolds, Christopher; Silver, Samuel; Reddy, Pavan; Becker, Michael; Ferrara, James L. M.; Uberti, Joseph P.

CORPORATE SOURCE: Blood and Marrow Stem Cell Transplantation Program, University of Michigan Health System, Ann Arbor, MI, USA

SOURCE:  Biology of Blood and Marrow Transplantation (2003), 9(8), 505-511

CODEN: BBMTF6; ISSN: 1083-8791

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We reviewed the clin. outcome of 8 patients with steroid-refractory chronic graft-vs.-host disease (GVHD) who received an anti-CD20 chimeric monoclonal antibody (rituximab). Rituximab was given by i.v. infusion at a weekly dose of 375 mg/m<sup>2</sup> for 4 wk. All patients had received extensive treatment with various immunosuppressive agents; 6 patients had also received extracorporeal photopheresis. All patients had extensive chronic GVHD with diffuse or localized sclerodermoid GVHD and xerophthalmia. Other extracutaneous involvements included cold agglutinin disease with the Raynaud phenomenon, membranous glomerulonephritis, and restrictive or obstructive lung disease. Four patients responded to treatment with ongoing resolu. or improvement ranging from 265 to 846 days after therapy, despite recovery of B cells in 3 patients. Rituximab seems to have significant activity in the treatment of refractory chronic GVHD and should be considered for further study in patients with early disease. This study suggests a participating role of B cells in the pathogenesis of chronic GVHD.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 29 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

ACCESSION NUMBER: 2003:328548 SCISEARCH

THE GENUINE ARTICLE: 662VH

TITLE: **Anti-CD20** monoclonal antibody in the treatment of patients with refractory chronic **graft versus host** disease

AUTHOR: Stamatovic D (Reprint); Tukic L; Tarabar O; Simic L; Malesevic M

SOURCE: BONE MARROW TRANSPLANTATION, (MAR 2003) Vol. 31, Supp. [1], pp. S131-S131.

Publisher: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND.

ISSN: 0268-3369.

DOCUMENT TYPE: Conference; Journal

LANGUAGE: English

REFERENCE COUNT: 0

L11 ANSWER 10 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2002:47987 USPATFULL

TITLE: Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications

INVENTOR(S): Hanna, Nabil, Rancho Santa Fe, CA, UNITED STATES  
Hariharan, Kandasamy, San Diego, CA, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2002028178 A1 20020307  
APPLICATION INFO.: US 2001-855717 A1 20010516 (9)

NUMBER DATE  
-----  
PRIORITY INFORMATION: US 2000-217706P 20000712 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Pillsbury Winthrop LLP, Intellectual Property Group,  
East Tower, Ninth Floor, 1100 New York Avenue, N.W.,  
Washington, DC, 20005-3918  
NUMBER OF CLAIMS: 103  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Page(s)  
LINE COUNT: 3047

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.

=>